Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

HepZero:Heparin Free Dialysis With Evodial

This study has been completed.
Statistical Analysis : CIC CHU Brabois Nancy
Gambro Lundia AB
Information provided by (Responsible Party):
Baxter Healthcare Corporation Identifier:
First received: March 11, 2011
Last updated: April 4, 2017
Last verified: April 2017
The study hypothesis is that with Evodial in patients requiring heparin free dialysis, the heparin free treatment can be performed easily (without saline flushes or blood predilution) and is at least not inferior and maybe superior to the standard care heparin free treatment in terms of clotting.

Condition Intervention
Chronic Kidney Disease
Patients Requiring Heparin Free Dialysis Treatments
Other: Heparin free dialysis technique
Device: Evodial

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: HepZero:Heparin Free Dialysis With Evodial: A Prospective Multicenter, Open, Randomized, Controlled Clinical Study With Parallel Groups

Resource links provided by NLM:

Further study details as provided by Baxter Healthcare Corporation:

Primary Outcome Measures:
  • Clotting of the dialysis session [ Time Frame: During first dialysis session_Dialysis duration: 4 hours ]

    To evaluate the rate of successful treatments, clotting in the air traps will be evaluated using a scale grading from 1 to 4 and previously described in the literature.

    The first heparin free dialysis treatment will be considered successful when there is:

    • No complete occlusion of air traps or dialyzer rendering dialysis impossible (grade 4 of the scale),
    • No additional saline flushes to prevent clotting,
    • No change of dialyzer or blood lines because of clotting
    • No premature stop (early rinse-back) because of clotting

Secondary Outcome Measures:
  • Clotting during consecutive dialysis session [ Time Frame: 2nd and 3rd consecutive dialysis sessions ]

    As for the first heparin free dialysis treatment, treatments will be considered successful when there is :

    • No complete occlusion of air traps or dialyzer rendering dialysis impossible (grade 4 of the scale),
    • No additional saline flushes to prevent clotting,
    • No change of dialyzer or blood lines because of clotting
    • No premature stop (early rinse-back) because of clotting.

  • Follow up of clotting during the dialysis sessions [ Time Frame: During all dialysis sessions ]
    • Grade 1: No detectable clotting
    • Grade 2: Minimal clot formation (Presence of fibrinous ring)
    • Grade 3: Clot formation (up to 5 cm) but dialysis still possible
    • Grade 4: complete occlusion of air traps or dialyzer rendering dialysis impossible

  • Efficacy [ Time Frame: During all dialysis sessions ]
    Measurement of urea, creatinine and ionogramm, UF achieved

  • Ease of use [ Time Frame: During all dialysis sessions ]
    Collection of saline flushes performed (volume and time)

  • Safety [ Time Frame: During all dialysis sessions ]
    Follow-up of AEs/SAEs

Enrollment: 266
Study Start Date: March 2011
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Heparin free dialysis standard of care
Standard of care: can be either saline flushes or predilution (on-line or bags)
Other: Heparin free dialysis technique
Saline flushes or predilution
Other Name: Standard of care
Experimental: Heparin free dialysis with Evodial Device: Evodial
Evodial dialyer


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients requiring heparin free dialysis treatments on nephrologists' prescription,
  • Chronic ESRD patients treated by maintenance hemodialysis for at least 3 months,
  • Patients with a well functioning blood access that can allow a blood flow of at least 250 ml/min,
  • Patients aged 18 years or more,
  • Written consent to participate in the study (informed consent).

Exclusion Criteria:

  • Patients in ICU settings,
  • AKI patients,
  • Patients dialyzed in self care, satellite HD units,
  • Patients treated in single needle mode,
  • Known heparin contraindication (HIT type II),
  • Patients requiring blood and other labile blood products (i.e. fresh frozen plasma, platelets, etc …) transfusion during hemodialysis treatment,
  • Patients receiving oral anticoagulants (including Anti vitamin K),
  • Patients receiving a combination of anti-platelets agents,
  • Patients treated with unfractionated or low molecular weight heparin beside the dialysis treatment to prevent deep vein thrombosis,
  • Pregnant/ planning pregnancy and lactating women during study period,
  • Adult patients protected by the law,
  • Patients are not affiliated to health insurance system (beneficiary or dependant)
  • Participation in other interventional studies during the study period,
  • Patients that have already been included in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01318486

Erasme Hospital
Brussels, Belgium
UZ Brussels
Brussels, Belgium
Canada, New Brunswick
George Dumont Hospital
Moncton, New Brunswick, Canada
CHU Edouard Herriot
Lyon, France
CHU Brabois
Nancy, France
CHU de Saint-Étienne - Hôpital Nord
Saint-Priest en Jarez, France, 42270
Groningen, Netherlands
Gdanski Uniwersytet Medyczny
Gdansk, Poland
Hospital Universitary German Trias i Pujol
Badalona, Spain, 08916
Vall d'Hebron Hospital
Barcelona, Spain
United Kingdom
Royal Liverpool University Hospital
Liverpool, United Kingdom
Sponsors and Collaborators
Baxter Healthcare Corporation
Statistical Analysis : CIC CHU Brabois Nancy
Gambro Lundia AB
Study Chair: Maurice Laville, Pr CHU Edouard Herriot Lyon
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Baxter Healthcare Corporation Identifier: NCT01318486     History of Changes
Other Study ID Numbers: 1483
Study First Received: March 11, 2011
Last Updated: April 4, 2017

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Calcium heparin
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 22, 2017